Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;26(7):2567-2577.
doi: 10.1111/dom.15565. Epub 2024 Apr 21.

Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history

Jin Hwa Kim  1 , Young Sang Lyu  1 , BongSeong Kim  2 , Mee Kyung Kim  3 , Sang Yong Kim  1 , Ki-Hyun Baek  3 , Ki-Ho Song  3 , Kyungdo Han  2 , Hyuk-Sang Kwon  3
Affiliations

Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history

Jin Hwa Kim et al. Diabetes Obes Metab. 2024 Jul.

Abstract

Aims: To evaluate the effects of initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors on cardiorenal outcomes and mortality compared to dipeptidyl peptidase-4 (DPP-4) inhibitors as active comparators in patients diagnosed with type 2 diabetes with a history of percutaneous coronary intervention (PCI).

Materials and methods: We used an active-comparator, new-user design and nationwide data from the National Health Insurance Service in South Korea from 2014 to 2019. Of the 56 392 patients who underwent PCI, 4610 new SGLT2 inhibitor users were paired 1:1 with DPP-4 inhibitor users for analysis using propensity-score matching.

Results: During 13 708.59 person-years of follow-up, the initiation of SGLT2 inhibitors, compared with the initiation of DPP-4 inhibitors, was associated with a significantly lower risk of composite repeat revascularization, myocardial infarction, stroke, heart failure (HF), all-cause death and end-stage renal disease (ESRD). The beneficial effects of SGLT2 inhibitor use were consistent with the components of stroke, HF, all-cause death and ESRD. In the cohort that included health examination data, including anthropometric and metabolic factors, new use of SGLT2 inhibitors was associated with a significantly lower risk of HF (hazard ratio [HR] 0.574, 95% confidence interval [CI] 0.36-0.915), all-cause death (HR 0.731, 95% CI 0.567-0.942), and ESRD (HR 0.076, 95% CI 0.018-0.319). The effects of SGLT2 inhibitor use were consistent regardless of the timing of the previous PCI.

Conclusions: The initiation of SGLT2 inhibitors in patients with type 2 diabetes and a history of PCI was significantly associated with a reduced risk of cardiorenal consequences and mortality, irrespective of time since the last PCI.

Keywords: SGLT2 inhibitor; percutaneous coronary intervention; type 2 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389(10085):2239‐2251.
    1. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke Statistics‐2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139‐e596.
    1. Bae JH, Han KD, Ko SH, et al. Diabetes fact sheet in Korea 2021. Diabetes Metab J. 2022;46(3):417‐426.
    1. Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug‐eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta‐analysis. Lancet. 2021;398(10318):2247‐2257.
    1. Gaudino M, Andreotti F, Kimura T. Current concepts in coronary artery revascularisation. Lancet. 2023;401(10388):1611‐1628.

MeSH terms

Substances